GoodRx (NASDAQ:GDRX) Major Shareholder Francisco Partners Iv, L.P. Sells 1,296,177 Shares of Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX) major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total transaction of $4,536,619.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Tuesday, August 25th, Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock. The shares were sold at an average price of $3.44, for a total transaction of $437,819.12.
• On Monday, August 24th, Francisco Partners Iv, L.P. sold 143,594 shares of GoodRx stock. The stock was sold at an average price of $3.46, for a total value of $496,835.24.
• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total value of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total value of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Stock Performance

NASDAQ:GDRX opened at $3.65 on Thursday. The business’s fifty day moving average is $3.18 and its 200 day moving average is $2.66. The firm has a market cap of $1.25 billion, a price-to-earnings ratio of 91.27, a PEG ratio of 1.73 and a beta of 1.60. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38. GoodRx Holdings, Inc. has a 52-week low of $1.77 and a 52-week high of $5.81.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, hitting the consensus estimate of $0.08. The business had revenue of $200.41 million during the quarter, compared to the consensus estimate of $193.23 million. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The firm’s revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.09 EPS. Research analysts predict that GoodRx Holdings, Inc. will post 0.16 EPS for the current year.

Analyst Ratings Changes

GDRX has been the subject of several recent analyst reports. Wall Street Zen raised shares of GoodRx from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Weiss Ratings raised shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, August 7th. Citigroup increased their target price on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Leerink Partners set a $5.00 price target on shares of GoodRx in a report on Thursday, August 6th. Finally, UBS Group boosted their price target on shares of GoodRx from $2.50 to $3.75 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, GoodRx presently has an average rating of “Hold” and a consensus target price of $4.23.

Institutional Trading of GoodRx

A number of large investors have recently modified their holdings of GDRX. Quarry LP bought a new position in shares of GoodRx in the third quarter worth approximately $33,000. Cetera Investment Advisers bought a new stake in GoodRx during the second quarter valued at approximately $50,000. Boothbay Fund Management LLC purchased a new position in GoodRx in the 3rd quarter worth approximately $43,000. Headlands Technologies LLC purchased a new position in GoodRx in the 2nd quarter worth approximately $30,000. Finally, Meridian Wealth Management LLC bought a new position in shares of GoodRx in the 4th quarter worth $29,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.